0 90

Cited 0 times in

Pediatric Patients with Refractory Central Nervous System Tumors: Experiences of a Clinical Trial Combining Bevacizumab and Temsirolimus

DC FieldValueLanguage
dc.contributor.author신상준-
dc.date.accessioned2015-01-06T17:20:20Z-
dc.date.available2015-01-06T17:20:20Z-
dc.date.issued2014-
dc.identifier.issn0250-7005-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/99793-
dc.description.abstractBACKGROUND: Pre-clinical findings suggest that combination treatment with bevacizumab and temsirolimus could be effective against malignant pediatric central nervous system (CNS) tumors. PATIENTS AND METHODS: Six pediatric patients were treated as part of a phase I trial with intravenous temsirolimus 25 mg on days 1, 8, 15, and bevacizumab at 5, 10, or 15 mg/kg on day 1 of each 21-day cycle until disease progression or patient withdrawal. RESULTS: The median patient age was six years (range=3-14 years). The primary diagnoses were glioblastoma multiforme (n=2), medullobalstoma (n=2), pontine glioma (n=1) and ependymoma (n=1). All patients had disease refractory to standard-of-care (2-3 prior systemic therapies). Grade 3 toxicities possibly related to drugs used occurred in two patients: anorexia, nausea, and weight loss in one, and thrombocytopenia and alanine aminotransferase elevation in another. One patient with glioblastoma multiforme achieved a partial response (51% regression) and two patients (with medulloblastoma and pontine glioma) had stable disease for four months or more (20 and 47 weeks, respectively). One other patient (with glioblastoma multiforme) showed 18% tumor regression (duration=12 weeks). CONCLUSION: The combination of bevacizumab with temsirolimus was well-tolerated and resulted in stable disease of at least four months/partial response in three out of six pediatric patients with chemorefractory CNS tumors.-
dc.description.statementOfResponsibilityopen-
dc.format.extent1939~1945-
dc.relation.isPartOfAnticancer Research-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.titlePediatric Patients with Refractory Central Nervous System Tumors: Experiences of a Clinical Trial Combining Bevacizumab and Temsirolimus-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학)-
dc.contributor.googleauthorSARINA A. PIHA-PAUL-
dc.contributor.googleauthorSANG JOON SHIN-
dc.contributor.googleauthorTRIBHAWAN VATS-
dc.contributor.googleauthorNANDITA GUHA-THAKURTA-
dc.contributor.googleauthorJOANN AARON-
dc.contributor.googleauthorMICHAEL RYTTING-
dc.contributor.googleauthorEUGENIE KLEINERMAN-
dc.contributor.googleauthorRAZELLE KURZROCK-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA02105-
dc.relation.journalcodeJ00188-
dc.identifier.urlhttp://ar.iiarjournals.org/content/34/4/1939.long-
dc.contributor.alternativeNameShin, Sang Joon-
dc.contributor.affiliatedAuthorShin, Sang Joon-
dc.rights.accessRightsfree-
dc.citation.volume34-
dc.citation.number4-
dc.citation.startPage1939-
dc.citation.endPage1945-
dc.identifier.bibliographicCitationAnticancer Research, Vol.34(4) : 1939-1945, 2014-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.